NO981201L - Fremgangsmåter og sammensetninger for å undertrykke en immunrespons ved anvendelse av hovedhistokompatibilitetskompleks (MHC) klasse II peptider - Google Patents
Fremgangsmåter og sammensetninger for å undertrykke en immunrespons ved anvendelse av hovedhistokompatibilitetskompleks (MHC) klasse II peptiderInfo
- Publication number
- NO981201L NO981201L NO981201A NO981201A NO981201L NO 981201 L NO981201 L NO 981201L NO 981201 A NO981201 A NO 981201A NO 981201 A NO981201 A NO 981201A NO 981201 L NO981201 L NO 981201L
- Authority
- NO
- Norway
- Prior art keywords
- class
- compositions
- methods
- immune response
- major histocompatibility
- Prior art date
Links
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title abstract 3
- 230000028993 immune response Effects 0.000 title abstract 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 2
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 230000000961 alloantigen Effects 0.000 abstract 1
- 239000000956 alloy Substances 0.000 abstract 1
- 229910045601 alloy Inorganic materials 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000016396 cytokine production Effects 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Fremgangsmåter og sammensetninger for å undertrykke en immunrespons ved anvendelse eller som omfatter peptidfragmenter fra alfa-kjeden til klasse II hoved-histokompatibilitetskomplekset inneholdende et sterkt konservert område og som er effektivt til å undertrykke minst en og fortrinnsvis alle av følgende: en blandet lymfocyttreaksjon eller annen T-celle allogjenkjenningsreaksjon; dannelse av cytotoksiske T-celler som gjenkjenner et alloantigen; lymfocyttproliferasjon overfor vevsantigen; og stimulatorisk cytokinproduksjon til lymfocytter. Immunresponser som kan bli stanset eller undertrykket innbefatter alloimmunitet og autoimmunitet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US411795P | 1995-09-21 | 1995-09-21 | |
| PCT/US1996/015662 WO1997010711A1 (en) | 1995-09-21 | 1996-09-23 | Methods and compositions for suppressing an immune response using major histocompatibility complex (mhc) class ii peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO981201L true NO981201L (no) | 1998-03-17 |
| NO981201D0 NO981201D0 (no) | 1998-03-17 |
Family
ID=21709234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO981201A NO981201D0 (no) | 1995-09-21 | 1998-03-17 | Fremgangsmåter og sammensetninger for å undertrykke en immunrespons ved anvendelse av hovedhistokompatibilitetskompleks (MHC) klasse II peptider |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0914041A4 (no) |
| JP (1) | JPH11513377A (no) |
| KR (1) | KR19990063637A (no) |
| AU (1) | AU7202596A (no) |
| BR (1) | BR9610625A (no) |
| CA (1) | CA2230119A1 (no) |
| HU (1) | HUP9901795A2 (no) |
| IL (1) | IL123759A0 (no) |
| NO (1) | NO981201D0 (no) |
| WO (1) | WO1997010711A1 (no) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7247438B1 (en) | 1997-02-18 | 2007-07-24 | Dana-Farber Cancer Institute | Methods of identifying agents which enhance caspase activity |
| JP2014133703A (ja) * | 2011-03-30 | 2014-07-24 | Clio Inc | 生体組織から単離できるｓｓｅａ−３陽性の多能性幹細胞を含む他家移植用細胞治療用組成物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08502244A (ja) * | 1992-08-11 | 1996-03-12 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 免疫調節ペプチド |
-
1996
- 1996-09-23 CA CA002230119A patent/CA2230119A1/en not_active Abandoned
- 1996-09-23 WO PCT/US1996/015662 patent/WO1997010711A1/en not_active Ceased
- 1996-09-23 BR BR9610625A patent/BR9610625A/pt not_active Application Discontinuation
- 1996-09-23 IL IL12375996A patent/IL123759A0/xx unknown
- 1996-09-23 JP JP9512976A patent/JPH11513377A/ja active Pending
- 1996-09-23 AU AU72025/96A patent/AU7202596A/en not_active Abandoned
- 1996-09-23 HU HU9901795A patent/HUP9901795A2/hu unknown
- 1996-09-23 KR KR1019980702086A patent/KR19990063637A/ko not_active Withdrawn
- 1996-09-23 EP EP96933201A patent/EP0914041A4/en not_active Withdrawn
-
1998
- 1998-03-17 NO NO981201A patent/NO981201D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU7202596A (en) | 1997-04-09 |
| IL123759A0 (en) | 1998-10-30 |
| EP0914041A1 (en) | 1999-05-12 |
| BR9610625A (pt) | 1999-03-16 |
| EP0914041A4 (en) | 2000-06-28 |
| NO981201D0 (no) | 1998-03-17 |
| WO1997010711A1 (en) | 1997-03-27 |
| HUP9901795A2 (hu) | 1999-09-28 |
| CA2230119A1 (en) | 1997-03-27 |
| KR19990063637A (ko) | 1999-07-26 |
| JPH11513377A (ja) | 1999-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lapointe et al. | CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells | |
| Braud et al. | Functions of nonclassical MHC and non-MHC-encoded class I molecules | |
| de Koster et al. | T cells sensitized to synthetic HLA-DR3 peptide give evidence of continuous presentation of denatured HLA-DR3 molecules by HLA-DP. | |
| Szekeres-Bartho et al. | The role ofγ/δT cells in the feto-maternal relationship | |
| Singh et al. | T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. | |
| Schols et al. | Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production | |
| Garza et al. | Frequency of molecular mimicry among T cell peptides as the basis for autoimmune disease and autoantibody induction | |
| van den Elsen et al. | Lack of CIITA expression is central to the absence of antigen presentation functions of trophoblast cells and is caused by methylation of the IFN-γ inducible promoter (PIV) of CIITA | |
| WO1999042564A3 (en) | Apoptotic cell-mediated antigen presentation to dendritic cells | |
| EP0703783A4 (en) | HLA-A2.1-BINDING PEPTIDES AND THEIR USE | |
| BG102439A (en) | Antitumor vaccine and method for its preparation | |
| EP0637249A4 (en) | SUPPRESSION OF PROLIFERATIVE REACTION AND PROVISION OF TOLERANCE USING CLASS II MHC POLYMORPHIC ALLOPEPTIDES. | |
| AU3925295A (en) | Novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases | |
| Leddon et al. | Generation of MHC class II–peptide ligands for CD4 T-cell allorecognition of MHC class II molecules | |
| IL92629A0 (en) | Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases | |
| Jensen et al. | Gliadin‐specific T cell responses in peripheral blood of healthy individuals involve T cells restricted by the coeliac disease associated DQ2 heterodimer | |
| Bosnes et al. | Recognition of a particular HLA‐DQ heterodimer by a human γ/δ T cell clone | |
| NO981201L (no) | Fremgangsmåter og sammensetninger for å undertrykke en immunrespons ved anvendelse av hovedhistokompatibilitetskompleks (MHC) klasse II peptider | |
| Res et al. | Heat shock proteins and autoimmunity in humans | |
| Palacios-Boix et al. | HLA-DR4 restricted lymphocyte proliferation to a Mycobacterium tuberculosis extract in rheumatoid arthritis and healthy subjects. | |
| Smith et al. | Peptide sequences binding to MHC class I proteins | |
| Lundin et al. | T lymphocyte clones recognizing an HLA-DQw3. 2-associated epitope involving residue 57 on the DQ β chain | |
| CA2157500A1 (en) | Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation | |
| López-Moratalla et al. | Inducible nitric oxide synthase in monocytes from patients with Graves’ disease | |
| Trieb et al. | Do heat shock proteins play a role in Graves' disease? Heat shock protein-specific T-cells from Graves' disease thyroids do not recognize thyroid epithelial cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |